Page 8 of 9 – SEC Filing Julian C. Baker and Stephen R. Biggar currently serve on the
Issuer’s Board of Directors (the “Board”) as representatives of the Funds. The policy of the Funds and the Adviser
does not permit principals or employees of the Adviser to receive compensation for serving as directors of the Issuer, and the
Funds are instead entitled to the pecuniary interest in the options to purchase Common Stock of the Issuer (“Stock Options”).
Julian C. Baker and Dr. Biggar have no voting or dispositive power and no pecuniary interest in the Stock Options previously disclosed
in amendments to this Schedule 13D. Other than through their control of the Adviser, Felix J. Baker and Julian C. Baker have neither
voting nor dispositive power and have no direct pecuniary interest in the Stock Options held by Dr. Biggar.
The Funds are instead entitled to the pecuniary interest in
the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.
Baker Bros. Advisors LP has voting and investment power over
the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.
The Adviser GP, and Felix J. Baker and Julian C. Baker as principals
of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition
of the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.
(c) The disclosure regarding the purchase of common stock of
the Issuer in the Offering described in Item 4 is incorporated by reference herein. Except as described in this Amendment No. 9,
none of the Reporting Persons has effected any transaction in the securities of the Issuer in the past 60 days.
(d) Certain securities of the Issuer are held directly
by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole
general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of
Baker Biotech Capital (GP), LLC.
Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.
Certain securities of the Issuer are held directly by 14159,
a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner
of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.
(e) Not applicable.
Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
Follow Acadia Pharmaceuticals Inc (NASDAQ:ACAD)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Julian C. Baker and Stephen R. Biggar currently serve on the
Issuer’s Board of Directors (the “Board”) as representatives of the Funds. The policy of the Funds and the Adviser
does not permit principals or employees of the Adviser to receive compensation for serving as directors of the Issuer, and the
Funds are instead entitled to the pecuniary interest in the options to purchase Common Stock of the Issuer (“Stock Options”).
Julian C. Baker and Dr. Biggar have no voting or dispositive power and no pecuniary interest in the Stock Options previously disclosed
in amendments to this Schedule 13D. Other than through their control of the Adviser, Felix J. Baker and Julian C. Baker have neither
voting nor dispositive power and have no direct pecuniary interest in the Stock Options held by Dr. Biggar.
The Funds are instead entitled to the pecuniary interest in
the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.
Baker Bros. Advisors LP has voting and investment power over
the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.
The Adviser GP, and Felix J. Baker and Julian C. Baker as principals
of the Adviser GP, may be deemed to have the power to vote or direct the vote of and the power to dispose or direct the disposition
of the Stock Options held by Julian C. Baker and Dr. Biggar previously disclosed in amendments to this Schedule 13D.
(c) The disclosure regarding the purchase of common stock of
the Issuer in the Offering described in Item 4 is incorporated by reference herein. Except as described in this Amendment No. 9,
none of the Reporting Persons has effected any transaction in the securities of the Issuer in the past 60 days.
(d) Certain securities of the Issuer are held directly
by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole
general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of
Baker Biotech Capital (GP), LLC.
Certain securities of the Issuer are held directly by Life Sciences,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the
sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling
members of Baker Brothers Life Sciences Capital (GP), LLC.
Certain securities of the Issuer are held directly by 14159,
a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole general partner
of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital (GP), LLC.
(e) Not applicable.
